aap launches world’s first human clinical study for antibacterial silver coating technology on anatomical plates and screws for fracture treatment

The aap Implantate AG ( ” aap ” or “Company”) announces that clinical human study was started for their innovative antibacterial silver coating technology on yesterday. The University Clinic in Regensburg is the first test center to be equipped with the appropriate study materials and trained to perform operations with the company’s silver-coated implants as part of the study.

With this, aap has reached another important milestone on the way to the planned CE approval and is at the same time the first company worldwide that will test an antibacterial silver coating on anatomical plates and screws for fracture treatment as part of a study of this kind.

With its antibacterial silver coating technology, aap addresses one of the greatest and so far not adequately solved challenges in traumatology: the reduction of infections in connection with the introduction of implants into the body (so-called Surgical Site Infections = SSI). Surgical site infections represent a major burden both for the affected patients and for the global health systems. A particular danger is posed by antibiotic-resistant bacteria. In its annual report on the state of research on overcoming antibiotic resistance, the WHO recently found that some of the most dangerous bacteria in the world have developed resistance to the known agents. [1]In addition, according to the WHO, almost all antibiotics currently being developed hardly work better than the existing agents. Aap’s innovative antibacterial silver coating technology represents an alternative solution in the fight against bacterial infections that is not based on antibiotics and therefore offers enormous market potential. As a platform technology, the technology has a wide range of applications and, in addition to traumatology, can be used in other areas of orthopedics as well as in cardiology, dentistry or medical instruments.

In the future , aap will report regularly on the progress of the clinical human study for its innovative silver coating technology .

[1] 2020 Antibacterial agents in clinical and preclinical development: an overview and analysis. Geneva: World Health Organization; 2021.

————————————————– ————————————————– —————————————
 Implantate AG (ISIN DE0005066609) – General Standard / regulated market – All German stock markets –

About aap Implantate AG
The aap Implantate AG is a global medical technology company with headquarters in Berlin, Germany. The company develops, manufactures and markets products for traumatology. In addition to the innovative anatomical plate system LOQTEQ (R), the IP-protected portfolio includes a wide range of cannulated screws. In addition, the aapImplantate AG has an innovation pipeline with promising development projects such as antibacterial silver coating technology and magnesium-based implants. These technologies address critical problems in traumatology that have not yet been adequately resolved. The aap Implantate AG sells its products in Germany directly to hospitals, buying syndicates and clinics, while primarily a wide distributor network is used in around 25 countries internationally. In the USA, the company and its subsidiary aapImplants Inc. on a hybrid sales strategy. Sales are carried out through distribution agents as well as through partnerships with global orthopedic companies. The aap Implantate AG share is listed in the General Standard of the Frankfurt Stock Exchange (XETRA: AAQ.DE). Please refer to our website below for more information www.aap.de .

-looking statements This release may contain forward-looking statements that are based on the current expectations, assumptions and forecasts of the Management Board and information currently available to it. The forward-looking statements are not to be understood as guarantees of future developments and results contained therein. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors also include those who have aapdescribed in published reports. Forward-looking statements are therefore only valid on the day on which they are made. We do not assume any obligation to update the forward-looking statements made in this release or to adapt them to future events or developments.

If you have any questions, please contact:
aap Implantate AG; Fabian Franke; Head of Investor Relations; Lorenzweg 5; D-12099 Berlin; Tel .: +49 (0) 30 75019 – 134; Fax .: +49 (0) 30 75019 – 290; Email: f.franke@aap.de

SOURCE: aap Implantate, December 10, 2021